About Hera Biolabs
Hera Biolabs is a company based in Lexington (United States) founded in 2015 was acquired by Demeetra in June 2025. Hera Biolabs has raised $3.39 million across 7 funding rounds from investors including HHS, Demeetra and Enterprise Angels Community Fund I. Hera Biolabs offers products and services including SRG Rat Platform, Cas-CLOVER, piggyBac, and Gene Editing Services. Hera Biolabs operates in a competitive market with competitors including Biocytogen, Applied StemCell, Interius Biotherapeutics, GemPharmatech and Nagi Bioscience, among others.
- Headquarter Lexington, United States
- SectorsHealthcare
- Phone•••• ••••
- Website herabiolabs.com
- Social LinkedIn X Facebook
- Acquired by Demeetra (Jun 2025)
Products & Services of Hera Biolabs
Hera Biolabs offers a comprehensive portfolio of products and services, including SRG Rat Platform, Cas-CLOVER, piggyBac, and Gene Editing Services.
Immunodeficient rat for human xenograft and oncology studies
System for custom nucleases and cell modifications
Non-viral tool for cell line engineering and transgenesis
Custom cell line and model development for R&D
Funding Insights of Hera Biolabs
Hera Biolabs has successfully raised a total of $3.39M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $1.07 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.39M
- Total Rounds 7
- Last Round Series A — $1.07M
- First Round $1.1M
(Feb 2015)
- Investors Count 2
All 7 funding rounds of Hera Biolabs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $1.07M | Series A | – | – | – |
| Apr 2018 | $525,000 | Seed | – | – | – |
| Dec 2016 | $400,000 | Grant | – | – | – |
| Sep 2016 | $700,000 | Seed | – | – | – |
| Sep 2015 | – | Grant | – | – | |
| Sep 2015 | $1.46M | Grant | – | – | |
| Feb 2015 | $1.1M | Seed | – | Enterprise Angels Community Fund I | – |
3 investors in total: 3 institutional.
Investors in Hera Biolabs
Hera Biolabs has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Demeetra and Enterprise Angels Community Fund I.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | enterpriseangelsfund.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Provider of gene-editing platform for pharmaceutical, agricultural, and industrial biotech firm | 2018 | demeetra.com | Lexington, United States |
Investor details for Hera Biolabs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Hera Biolabs
1 people are tracked at Hera Biolabs (1 in team).
| Name | Role | Group |
|---|---|---|
Abigail Ross | Cell Lab Manager | Team |
Complete people profiles for Hera Biolabs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Hera Biolabs
4 dated milestones of Hera Biolabs across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Hera Biolabs is founded.
- Funding First funding round of $1.1M.
- Funding Latest funding round, Series A, of $1.1M.
- Exit Acquired by Demeetra.
Competitors of Hera Biolabs
Hera Biolabs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biocytogen, Applied StemCell, Interius Biotherapeutics, GemPharmatech and Nagi Bioscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biocytogen.com | 2008 | Wakefield, United States | $301.11M | 85 | Integrated solutions for next-generation antibody drug development are provided. | |
| appliedstemcell.com | 2008 | Milpitas, United States | $67.52M | 53 | Provider of animal and cell line models as tools for drug discovery and diagnostics | |
| interiusbio.com | 2020 | Philadelphia, United States | $129.03M | 25 | Developer of gene therapies for treating multiple diseases | |
| gempharmatech.com | 2018 | Nanjing, China | $81.85M | 10 | Humanized models and drug screening technologies are developed for research. | |
| nagibio.ch | 2017 | Lausanne, Switzerland | $1.84M | – | Developer of a organism on a chip based technology | |
| businesscatalyst.com | 2004 | San Jose, United States | $1.25M | 9,771 | In-vivo mouse models are developed for biomedical R&D applications. | |
| lingfubio.tcc.mode | 2021 | Beijing, China | $30.76M | – | Animal research service provider that offers animal behavior analysis services | |
| bioreperia.com | 2015 | Stockholm, Sweden | $882,454 | – | Zebrafish models are developed for oncology and toxicology applications. | |
| axenis.fr | 2010 | Paris, France | – | – | Chimeric in-vivo mouse models for biomedical research are developed. |
Detailed competitors of Hera Biolabs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Hera Biolabs
Websites that share an audience with Hera Biolabs (herabiolabs.com).
Websites whose visitors overlap most with Hera Biolabs. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| systembio.com | 100% | 23.8K | #1,129,361 | View details | |
| biocat.com | 78% | 37.9K | #866,969 | View details | |
| cytion.com | 78% | 115.2K | #382,206 | View details | |
| bioscience.co.uk | 78% | 58K | #534,137 | View details | |
cellosaurus.org | cellosaurus.org | 78% | – | #349,270 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Hera Biolabs
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Hera Biolabs
Complete news archive for Hera Biolabs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Hera Biolabs
10 companies that operate in the same segment as Hera Biolabs (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Hera Biolabs
Hera Biolabs was founded in 2015.
Hera Biolabs is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Hera Biolabs is a funded company, having raised a total of $3.39M across 7 funding rounds to date. The company's 1st funding round was a Seed of $1.1M, raised on Feb 2015.
Hera BioLabs is a CRO developing rodent models utilizing gene-editing technologies to create improved preclinical models. They combine these models with toxicology and efficacy studies to produce high-confidence, translational data. They call this Precision Toxicology and Efficacy Screening. Hera has successfully developed several fully severe combined immunodeficient (SCID) rat lines with applications in tumor cell line xenografts and patient-derived xenograft (PDX) efficacy screening. Furthermore, the humanization of the liver and immune system in Heras rat models is also underway, which is expected to impact human-specific liver toxicity screening, the availability of human hepatocytes, and the industrys ability to test for human-specific metabolites.
Hera Biolabs's top competitors include Biocytogen, Applied StemCell and GemPharmatech.
Hera Biolabs offers SRG Rat Platform, Cas-CLOVER, piggyBac, and Gene Editing Services.
Yes. Hera Biolabs was acquired by Demeetra in June 2025.